Eli Lilly advanced its triple-G obesity program after new Phase 3 results positioned retatrutide (retatrutide/“reta”) for an FDA filing. The company said additional obesity trial data cleared key endpoints, including results from studies that added medically higher-risk populations such as type 2 diabetes and cardiovascular complications. Lilly framed the datasets as supportive of a regulatory submission timeline early next year, while analysts highlighted that the evidence base for cardiovascular risk reduction remains less definitive than weight-loss efficacy. The next regulatory milestone will turn on how reviewers weigh the magnitude of weight loss versus clinical endpoints tied to cardiovascular outcomes. The retatrutide update extends intense competition in obesity/diabetes incretin-based pharmacology, where endpoints, dosing, and cardiometabolic risk signals increasingly determine market positioning and payer uptake.